-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213

Benzinga·08/03/2026 14:06:58
Listen to the news
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $213.